Neutrophil chemotaxis was evaluated in patients with staphylococcal furunculosis using a modified Boyden chamber assay. Neutrophil chemotactic response to Staphylococcus aureus-derived chemotactic factor was compared with response to Escherichia coli-derived chemotactic factor and zymosan-activated serum. Twenty-one patients with active furunculosis were compared with 29 patients with a history of furunculosis but no recent infection and with 29 healthy control subjects. Chemotactic response to the staphylococcal chemotactic factor was significantly higher in patients with active furunculosis (mean 61.6) than in patients with a history of furunculosis (mean 36.4) or controls (mean 31.4), P < 0.001. Neutrophils from patients with active staphylococcal infections also had higher chemotactic activity toward E. coli chemotactic factor, but not significantly so (P = 0.09). Chemotactic response to zymosan-activated serum and background neutrophil motility was comparable among the three groups. The increased neutrophil chemotactic response of patients with active infection to bacterial factors, but not zymosan-activated serum, may represent a specific neutrophil response to products of infecting organisms. The differential response of the patients' neutrophils to these attractants supports evidence for the presence of separate categories of chemotaxin receptor on the surface of neutrophils.
Most normal individuals are colonized with Staphylococcus aureus at one time or another, but relatively few develop staphylococcal infections. The propensity for certain individuals to develop recurrent staphylococcal furunculosis is not fully understood. Factors such as inoculum size, virulence of the organism, and integrity of skin and mucosal barriers may be important in some instances, but as in any type of recurrent infection, an abnormality of the immune response must be suspected. Since recurrent staphylococcal infection has been associated with decreased neutrophil chemotaxis in such disorders as the hyperimmunoglobulinemia E and Chediak-Higashi syndromes, a prospective study of neutrophil chemotaxis was performed in patients with recurrent staphylococcal furunculosis (2, 5, 10, 12) .
A S. aureus-derived chemotactic factor was employed as a chemotaxin in this study since S. aureus was the primary infecting agent in these patients. In addition, two standard attractants, Escherichia coli chemotactic factor and zymosan-activated serum, were used.
MATERLALS AND METHODS 4 weeks of study. Three patients were studied longitudinally, both with and without infection, and therefore appear in both groups. Eight of the patients with active furunculosis had known underlying diseases. Six had hyperimmunoglobulinemia E syndrome, one had chronic granulomatous disease, and one had Wiskott-Aldrich syndrome. Six patients with past furunculosis had underlying diseases. Three had hyperimmunoglobulinemia E syndrome, two had chronic granulomatous disease, and one had Wiskott-Aldrich syndrome. The rest of the patients in the two groups had no known underlying disease which might account for their recurrent staphylococcal infections. Controls consisted of 29 healthy laboratory personnel.
Leukocyte preparation. Leukocytes were prepared by dextran sedimentation of heparinized venous blood (10 U of heparin per ml of whole blood) using methods previously described (3). After washing, leukocytes were suspended at a concentration of 2 x 106 polymorphonuclear leukocytes per ml in Hanks balanced salt solution with 10% autologous plasma.
Chemotactic factor preparation. Bacterial chemotactic factors were prepared from S. aureus
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502A and a laboratory strain of E. coli provided by Peter Ward. Cultures were maintained on nutrient agar at 40C. One loopful of bacteria was inoculated into 100 ml of tissue culture medium 199 (Microbiological Associates). After incubation at 370C for 24 h, the suspension was centrifuged and the supernatant was filtered. Aliquots were stored at -70C. The S.
aureus supernatant was diluted 1:1 in Hanks balanced salt solution, and the E. coli supernatant was diluted 1:20 in Hanks balanced salt solution for use as chemoattractants.
Zymosan-activated serum was prepared as previously described (3). The activated serum was diluted 1:10 for use as a chemoattractant.
Neutrophil chemotaxis assay. Neutrophil chemotaxis was measured using a previously described modification of the Boyden chamber technique with membrane filters (5 um pore size; Millipore Corp.) (3). Briefly, 0.4 ml of the leukocyte suspension was added to the upper compartment of a modified Boyden chamber (Neuroprobe, Inc.). The chemotaxin was added to the lower compartment in the concentrations stated above. Hanks balanced salt solution alone was used in the lower compartment to assess background neutrophil motility. After 2 h of incubation at 370C, filters were removed from the chambers, fixed, stained, dehydrated, and mounted. Chemotactic activity was quantitated by determining the number of neutrophils adhering to the chemoattractant side of the filter inside a grid (5 by 5 mm) in 10 randomly selected highpower fields. Results represent the average of triplicate determinations.
RESULTS
The neutrophil chemotactic response to the staphylococcal-derived chemotactic factor is shown in Fig. 1 . Chemotactic response to the staphylococcal chemotactic factor was significantly higher in patients with active staphylococcal infection within 2 weeks of study (mean 61.6) than in patients with past infections (mean 36.4) and control subjects (mean 31.4; P< 0.001). Patients with active staphylococcal infection also had higher chemotactic response to the E. coli-derived factor than the other two groups (mean 95.0, versus 75.5 for patients with past infection and 72.1 for controls), but this difference is not statistically significant (P = 0.09) (Fig. 2) .
In Three patients were studied both during active staphylococcal infection and at least 4 weeks after infection. In each of the three patients, chemotactic activity toward the S. aureus chemotactic factor was elevated during active staphylococcal infection but returned to normal upon resolution of the infection (Fig. 4) .
Neutrophil chemotaxis has been evaluated in patients with acute "non-staphylococcal" infections, primarily Streptococcus pyogenes and Streptococcus pneumoniae. Mean oratory. Furthermore, neutrophil chemotaxis was not increased in patients with acute nonstaphylococcal infections. The wide range of neutrophil chemotaxis in controls and patient groups to the three chemoattractants makes it difficult to draw firm conclusions; however, the increased activity in patients with active staphylococcal infection toward the staphylococcal factor is statistically significant.
Products from several species of bacteria have been demonstrated to be active chemotaxins for leukocytes (11, 13, 16, 17) . In addition to chemotaxins, bacteria can also produce chemotaxigens, that is, substances which activate serum causing the release of chemotaxins (6, 7, 8, 15) . Studies have shown that crude suspensions of S. aureus, purified staphylococcal cell wall preparations, peptidoglycan, protein A, and enterotoxin B are chemotaxigenic (6, 7, 8, 14a, 15) . Experiments using heated serum and anti-C5a suggest that the active chemotaxin produced by these staphylococcal products is C5a (14a). The increased chemotactic response seen in patients with active S. aureus infection was toward a staphylococcal chemotaxin rather than zymo-san-activated serum which contains the same kind of product, C5a, produced by staphylococcal chemotaxigens.
In separate studies, Aswanikumar et al. and Chenoweth et al. have shown that the receptor on the neutrophil surface for chemotaxins related to the E. coli chemotactic factor is distinct from that for C5a (1, 4, 14) . Our finding an increase in chemotactic response to one factor, that derived from S. aureus, but not to zymosanactivated serum in a group of patients is consistent with the presence of separate receptors on the surface of the neutrophil for different attractants. Furthermore, it suggests that clinical circumstances may dictate which neutrophil receptor is activated.
It is tempting to postulate that hyperactive neutrophil response to the staphylococcal chemotactic factor may be responsible for the large pus-filled lesions in patients with active staphylococcal infection. It is possible, however, that it represents the normal specific host response to bacterial invasion.
